Raise closed, search for fresh raises on Seedstage

Torrance, CA

Developing a rapid blood test for tacrolimus to improve monitoring and outcomes for organ transplant patients.

• Mission: Developing a rapid, user-friendly blood test for tacrolimus to improve medication monitoring and outcomes for organ transplant patients.  
• Innovation: Offering a faster, less invasive diagnostic solution that provides results in just 15 minutes, enabling timely dose adjustments to reduce risks like toxicity and transplant rejection.  
• Healthcare Impact: Enhancing patient care by facilitating quicker and more accurate monitoring of tacrolimus levels, which is crucial for improving transplant success and patient health.  
• Regulatory Progress: With FDA agreement on the regulatory pathway, MISAA is poised to make a significant impact in the transplant community through its innovative monitoring solution.  
• Funding Uses: Allocating funds for clinical trials, product development, and operational costs to advance the rapid blood test for tacrolimus and bring it to market.  
• Partnerships: Collaborating with IOS to leverage advanced sensing technologies, ensuring efficient development and market entry for its groundbreaking diagnostic tool.  

MISAA is focused on developing a rapid blood test for tacrolimus, an essential immunosuppressive drug for organ transplant patients, which will allow for timely monitoring and adjustments of medication levels. This innovative test is designed to be less invasive and more user-friendly, providing results in just 15 minutes, which is a significant improvement over traditional methods that can take days.

By enabling quicker dose adjustments, the test aims to enhance patient outcomes and reduce the risks associated with tacrolimus therapy, such as toxicity and transplant rejection. The company has partnered with IOS, leveraging their expertise in advanced sensing technologies to bring this product to market efficiently.

With the FDA’s agreement on the regulatory pathway for approval, MISAA is well-positioned to make a meaningful impact on the transplant community. The funds raised through this offering will support clinical trials, product development, and operational costs, ultimately driving the mission to improve the health and well-being of transplant recipients and their caregivers through innovative monitoring solutions.

Company Info

MISAA develops in vitro diagnostic devices to improve the transplant community.

MISAA is a company focused on transforming the transplant community through innovative in vitro diagnostic devices. Their mission is to enhance the effectiveness and accessibility of transplant-related testing, aiming to improve patient outcomes. By leveraging advanced technology, MISAA seeks to provide valuable insights that can aid in the transplant process. The company is dedicated to unlocking the full potential of its diagnostic devices, which are designed to meet the specific needs of the transplant community. Through their efforts, MISAA aims to make a significant impact on the field of transplantation and support healthcare providers in delivering better care to patients.